GSK plc

More Details of GSK plc Company

Company Info

Company codeGSK

Company nameGSK plc

IPO dateMay 22, 1972

Founded at1999

CEOMs. Deborah Waterhouse

Number of employees68629

Security typeOrdinary Share

Fiscal year-endMay 22

Address980 Great West Road

CityBRENTFORD

Stock exchangeLondon Stock Exchange

CountryUnited Kingdom

Postal codeTW8 9GS

Phone442080475000

Websitehttps://www.gsk.com/

Company codeGSK

IPO dateMay 22, 1972

Founded at1999

Company Executives

Name

Name/Position

Position

Shareholding

Change

Dr. Hal V. Barron, M.D.

Non-Executive Director

679.87K

+3.73%

Ms. Shobie Ramakrishnan

Chief Digital and Technology Officer

483.75K

+7.69%

Mr. Charles A. (Charlie) Bancroft

Senior Independent Non-Executive Director

31.40K

+0.44%

Dr. Jesse Goodman, M.D.

Non-Executive Independent Director, Scientific and Medical Expert

15.11K

+0.12%

Dr. Anne Beal

Independent Non-Executive Director

3.81K

+0.47%

Ms. Elizabeth McKee (Liz) Anderson

Independent Non-Executive Director

2.18K

+0.97%

Dr. Jeannie Lee

Independent Non-Executive Director

796.00

+0.76%

Mr. David S. Redfern

President - Corporate Development

--

Ms. Diana Conrad

Chief People Officer

--

Dr. Harry C. (Hal) Dietz

Independent Non-Executive Director, Scientific and Medical Expert

--

Name

Name/Position

Position

Shareholding

Change

Dr. Hal V. Barron, M.D.

Non-Executive Director

679.87K

+3.73%

Ms. Shobie Ramakrishnan

Chief Digital and Technology Officer

483.75K

+7.69%

Mr. Charles A. (Charlie) Bancroft

Senior Independent Non-Executive Director

31.40K

+0.44%

Dr. Jesse Goodman, M.D.

Non-Executive Independent Director, Scientific and Medical Expert

15.11K

+0.12%

Dr. Anne Beal

Independent Non-Executive Director

3.81K

+0.47%

Ms. Elizabeth McKee (Liz) Anderson

Independent Non-Executive Director

2.18K

+0.97%

Revenue Breakdown

Currency: USDUpdate time: Wed, Mar 5

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Respiratory

9.21B

22.98%

HIV

9.05B

22.59%

Shingles

4.29B

10.72%

Established Vaccines

4.26B

10.64%

Immuno-inflammation

4.21B

10.51%

Other

9.03B

22.53%

By RegionUSD

Name

Revenue

Proportion

US

20.93B

52.21%

Rest of world

18.24B

45.52%

UK

904.52M

2.25%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Respiratory

9.21B

22.98%

HIV

9.05B

22.59%

Shingles

4.29B

10.72%

Established Vaccines

4.26B

10.64%

Immuno-inflammation

4.21B

10.51%

Other

9.03B

22.53%

Shareholder

Update time: Fri, Feb 21

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

Dodge & Cox

3.30%

Fidelity Management & Research Company LLC

2.11%

PRIMECAP Management Company

1.21%

JTC Employer Solutions Trusteee Ltd

0.97%

Fisher Investments

0.90%

Other

91.47%

Shareholder Statistics

Shareholder

Proportion

Dodge & Cox

3.30%

Fidelity Management & Research Company LLC

2.11%

PRIMECAP Management Company

1.21%

JTC Employer Solutions Trusteee Ltd

0.97%

Fisher Investments

0.90%

Other

91.47%

Type

Shareholder

Proportion

Investment Advisor

8.92%

Investment Advisor/Hedge Fund

6.17%

Hedge Fund

0.95%

Research Firm

0.70%

Bank and Trust

0.08%

Holding Company

0.06%

Individual Investor

0.05%

Pension Fund

0.05%

Insurance Company

0.05%

Other

82.90%

Institutional Shareholding

Update time: Sun, Jan 19

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

1428

354.30M

17.09%

+26.99M

2024Q4

1481

355.05M

17.14%

+27.37M

2024Q3

1472

319.96M

15.44%

-30.07M

2024Q2

1585

322.06M

15.54%

-29.11M

2024Q1

1617

318.91M

15.39%

-23.51M

2023Q4

1614

299.80M

14.57%

-35.70M

2023Q3

1570

293.92M

14.35%

-37.45M

2023Q2

1545

286.57M

13.99%

-41.87M

2023Q1

1546

281.07M

13.72%

-55.01M

2022Q4

1546

286.90M

13.32%

-22.15M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

Dodge & Cox

68.44M

3.3%

+353.74K

+0.51%

Dec 31, 2024

Fidelity Management & Research Company LLC

43.77M

2.11%

+18.13M

+70.76%

Dec 31, 2024

PRIMECAP Management Company

25.26M

1.21%

+10.40M

+70.06%

Dec 31, 2024

JTC Employer Solutions Trusteee Ltd

20.27M

0.97%

-202.39K

-0.98%

Dec 31, 2024

Fisher Investments

18.83M

0.9%

+259.86K

+1.39%

Dec 31, 2024

Fidelity Institutional Asset Management

9.05M

0.43%

+5.67M

+168.16%

Dec 31, 2024

Goldman Sachs Asset Management, L.P.

8.85M

0.42%

+1.77M

+25.03%

Dec 31, 2024

T. Rowe Price International Ltd

7.56M

0.36%

+35.10K

+0.46%

Dec 31, 2024

State Street Global Advisors (US)

7.02M

0.33%

+247.17K

+3.64%

Dec 31, 2024

UBS Financial Services, Inc.

6.34M

0.3%

+5.68M

+871.38%

Dec 31, 2024

Related ETFs

Update time: 12 hours ago

Name

Proportion

VanEck Pharmaceutical ETF

4.3%

Sound Equity Dividend Income ETF

3%

Keating Active ETF

2.96%

Brandes International ETF

2.71%

Altrius Global Dividend ETF

1.83%

Pacer Global Cash Cows Dividend ETF

1.75%

USCF Dividend Income Fund

1.73%

Fidelity Blue Chip Value ETF

1.29%

Fidelity Women's Leadership ETF

1%

Hartford Multifactor Diversified International ETF

0.78%

VanEck Pharmaceutical ETF

Proportion4.3%

Sound Equity Dividend Income ETF

Proportion3%

Keating Active ETF

Proportion2.96%

Brandes International ETF

Proportion2.71%

Altrius Global Dividend ETF

Proportion1.83%

Pacer Global Cash Cows Dividend ETF

Proportion1.75%

USCF Dividend Income Fund

Proportion1.73%

Fidelity Blue Chip Value ETF

Proportion1.29%

Fidelity Women's Leadership ETF

Proportion1%

Hartford Multifactor Diversified International ETF

Proportion0.78%

Dividend

A total of 20.78B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Feb 05, 2025

GSK.NB Approximate interim Cash Dividend of gross USD 0.400652 paid on Apr 10, 2025 going ex on Feb 21, 2025

Feb 21, 2025

Apr 10, 2025

Feb 21, 2025

Oct 30, 2024

GSK.NB Final Cash Dividend of gross USD 0.376892 paid on Jan 09, 2025 going ex on Nov 15, 2024

Nov 15, 2024

Jan 09, 2025

Nov 15, 2024

Jul 31, 2024

GSK.NB Interim Cash Dividend of gross USD 0.392813 paid on Oct 10, 2024 going ex on Aug 16, 2024

Aug 16, 2024

Oct 10, 2024

Aug 16, 2024

May 01, 2024

GSK.NB Interim Cash Dividend of gross USD 0.384301 paid on Jul 11, 2024 going ex on May 16, 2024

May 17, 2024

Jul 11, 2024

May 16, 2024

Feb 01, 2024

GSK.NB Interim Cash Dividend of gross USD 0.404885 paid on Apr 11, 2024 going ex on Feb 22, 2024

Feb 23, 2024

Apr 11, 2024

Feb 22, 2024

Nov 01, 2023

GSK.NB Final Cash Dividend of gross USD 0.356356 paid on Jan 11, 2024 going ex on Nov 16, 2023

Nov 17, 2023

Jan 11, 2024

Nov 16, 2023

Jul 26, 2023

GSK.NB Interim Cash Dividend of gross USD 0.343532 paid on Oct 12, 2023 going ex on Aug 17, 2023

Aug 18, 2023

Oct 12, 2023

Aug 17, 2023

Apr 26, 2023

GSK.NB Interim Cash Dividend of gross USD 0.360944 paid on Jul 13, 2023 going ex on May 18, 2023

May 19, 2023

Jul 13, 2023

May 18, 2023

Feb 01, 2023

GSK.NB Interim Cash Dividend of gross USD 0.341883 paid on Apr 13, 2023 going ex on Feb 23, 2023

Feb 24, 2023

Apr 13, 2023

Feb 23, 2023

Nov 02, 2022

GSK.NB Final Cash Dividend of gross USD 0.334785 paid on Jan 12, 2023 going ex on Nov 17, 2022

Nov 18, 2022

Jan 12, 2023

Nov 17, 2022

Stock Split

Date

Type

Ratio

Jun 24, 2022

Merger

5<4

Jun 24, 2022

Merger

5<4

Jun 24, 2022

Merger

5<4

Jun 24, 2022

Merger

5<4

Date

Type

Ratio

Jun 24, 2022

Merger

5<4

Jun 24, 2022

Merger

5<4

Jun 24, 2022

Merger

5<4

Jun 24, 2022

Merger

5<4

38.430USD

GSK plc

38.430

Overview

Company